Results 271 to 280 of about 41,938 (307)

Discovery and development of bispecific antibodies

Protein Expression and Purification
Bispecific antibodies (BsAbs) represent a significant breakthrough in antibody-based therapeutics, offering the unique capability to engage two distinct targets simultaneously. BsAbs are expected to exert therapeutic effects that are unattainable with conventional antibody drugs. Specifically, they are being developed for use in intercellular bridging,
Tetsuya Wakabayashi, Taichi Kuramochi
openaire   +2 more sources

Bispecific antibodies rise again

Nature Reviews Drug Discovery, 2014
Amgen's blinatumomab is setting the stage for a bispecific revival, enabled by new formats that may solve the field's long-standing problems.
openaire   +2 more sources

Introduction: bispecific antibodies

Journal of Immunological Methods, 2001
D M, Segal, G J, Weiner, L M, Weiner
openaire   +2 more sources

Bispecific Antibody Therapy in Hemophilia

New England Journal of Medicine, 2017
Hemophilia A is the most common severe inherited bleeding disorder in humans. Bleeding occurs as a result of a deficiency or dysfunction of the procoagulant cofactor protein, factor VIII. For the past 50 years, the treatment and prevention of bleeding in hemophilia A has involved the intravenous infusion of plasma-derived or recombinant factor VIII ...
openaire   +2 more sources

Bispecific Antibodies for Cancer Therapy

Immunotherapy, 2009
Bispecific antibodies, in contrast to conventional monoclonal antibodies, can bind simultaneously two different antigens. Taking advantage of this virtue, they are mostly designed for immune effector cell redirection to tumors and for radionuclide pretargeting to tumors.
openaire   +2 more sources

How to Make Bispecific Antibodies

2000
This protocol describes the production of bispecific F(ab')2 antibody derivatives (BsAbs) by the linking of two Fab' fragments via their hinge region SH groups using the bifunctional crosslinker o-phenylenedimaleimide (o-PDM) as described by Glennie et al. (1,2). The procedure is illustrated in Fig. 1.
openaire   +2 more sources

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody

Cell, 2022
Cheng Li, Yan-Ning Qian, You-Hua Xie
exaly  

A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

Molecular Therapy, 2021
Jianhua Sui
exaly  

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

Cancers, 2021
Jim Middelburg, Patrick J Engelberts, Aran F Labrijn   +2 more
exaly  

Assessing the toxicity of bispecific antibodies

Nature Biomedical Engineering, 2023
Marta Buzzetti, Marco Gerlinger
openaire   +2 more sources